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Abstract
Background: This paper describes and analyses Rwanda’s science-based health product ‘innovation system’,
highlighting examples of indigenous innovation and good practice. We use an innovation systems framework,
which takes into account the wide variety of stakeholders and knowledge flows contributing to the innovation
process. The study takes into account the destruction of the country’s scientific infrastructure and human capital
that occurred during the 1994 genocide, and describes government policy, research institutes and universities, the
private sector, and NGOs that are involved in health product innovation in Rwanda.
Methods: Case study research methodology was used. Data were collected through reviews of academic literature
and policy documents and through open-ended, face-to-face interviews with 38 people from across the science-
based health innovation system. Data was collected over two visits to Rwanda between November – December
2007 and in May 2008. A workshop was held in Kigali on May 23rd and May 24th 2009 to validate the findings. A
business plan was then developed to operationalize the findings.
Results and discussion: The results of the study show that Rwanda has strong government will to support health
innovation both through its political leadership and through government policy documents. However, it has a very
weak scientific base as most of its scientific infrastructure as well as human capital were destroyed during the 1994
genocide. The regulatory agency is weak and its nascent private sector is ill-equipped to drive health innovation. In
addition, there are no linkages between the various actors in the country’s health innovation system i.e between
research institutions, universities, the private sector, and government bureaucrats.
Conclusions: Despite the fact that the 1994 genocide destroyed most of the scientific infrastructure and human
capital, the country has made remarkable progress towards developing its health innovation system, mainly due to
political goodwill. The areas of greatest potential for Rwanda are in traditional plant technologies. However, there is
need for investments in domestic skill development as well as infrastructure that will enhance innovation. Of
foremost importance is the establishment of a platform to link the various actors in the health innovation system.
Background
In the years between 1996 and 2005, Rwanda registered
an impressive annual economic growth rate averaging
about 8 per cent [1]. This growth took place despite the
fact that Rwanda is one of Sub-Saharan Africa’s smallest
countries, and had just emerged from a traumatic his-
tory of political upheaval that culminated in genocide in
1994. The country’s population of 9.5 million [2] inha-
bits a landscape of only 26,000 sq km, making it one of
Africa’s most densely populated countries. Its domestic
economy is characterized by low technology enterprises
dominated by commodity trading and basic services.
The country is faced with many structural challenges—it
is land-locked, has very few natural resources, and relies
almost entirely on earnings from exports of high volume
and low value agricultural products such as tea and cof-
fee, making it very susceptible to the whims of the glo-
bal market.
Rwanda’s economic growth, so soon after the destruc-
tion of the country’s infrastructure and human capital
during the genocide, was a result of several factors
including strong political leadership, much international
support, and the zeal and optimism of its people.
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2008 [3], mainly due to bad climatic conditions that
affected its agricultural exports, it still compares favour-
ably to most countries in Sub-Saharan Africa.
Rwanda’si m p r e s s i v ee c o n o m i cg r o w t hh a sn o t ,h o w -
ever, yet been fully translated to improved socioeco-
nomic status for all segments of the population. The
country’s per capita GDP at only US $230 (41% from
agriculture, 38% from tourism and 21% from industry,
mainly construction) means that poverty levels are still
high [4], with more than 64 % of all households in the
country living below the poverty line. 85 % of those liv-
ing below the poverty line are in rural areas. Only 41%
of the population had access to safe drinking water in
2008, while just over 50 % had access to safe sanitation
[5]. As a result, the incidence of diarrheal diseases is
high, partly contributing to the high infant mortality
rate which, at 119 per 1000, remains well above sub-
Saharan Africa’s average [6]. Such factors coupled with
the high incidence of malaria and HIV/AIDS limit the
average life expectancy to only 49 years.
Rwanda’s national innovation system may be described
as still very underdeveloped, but changes that have
occurred in the country’s economy since the genocide
are positively reflected in the innovation system. The
country still ranks very low in knowledge indicators,
having an innovation index of 1.22 out of 10 [7], having
less than 30 ISI publications between 2002 and 2004 [8]
and zero patents between 2000 and 2004 [9]. However
it has made tremendous investments to improve this,
including, for example, providing universal free primary
school education, expanding higher education opportu-
nities, and establishing collaborations and training pro-
grams with foreign universities. In fact, the number of
students in higher education has risen from only around
1,000 students in one University in 1994 to more than
27, 787 in 2005, 39% of them female [10]. The domestic
scientific skill base remains weak, but the government is
attempting to counter this by pursuing a very liberal
policy towards hiring of appropriate expatriate staff, e.g.,
nationals of the East African community member coun-
tries do not require work permits to work in Rwanda.
The government is also encouraging members of the
Rwandese diaspora to lend their expertise. To bolster
the nascent private sector and the almost non-existent
manufacturing base, reforms have been introduced to
ease the cost of doing business in Rwanda. These
include hastening the pace of registration of new busi-
nesses as well as increasing efficiency in enforcing con-
tracts [11].
In this paper we present research on science-based
health innovation in Rwanda, including biotechnology.
By science-based health innovation, we mean technolo-
gical innovation across a spectrum of sophistication,
from vaccines, pharmaceuticals, and medical devices to
some plant medicines where attempts to scientifically
standardize or characterize medicines have been made.
We take a broad definition of innovation as not only
new-to-the-world innovation, but also the diffusion,
adaptation and use of technologies. We use the OECD
definition of biotechnology: ‘the application of science
and technology to living organisms, as well as the parts,
products and models thereof, to alter living or non-liv-
ing materials for the production of knowledge, goods
and services’ [12].
The purpose of this paper is to describe and analyze
Rwanda’s science-based health innovation using an
innovation systems framework, which takes into account
the wide variety of stakeholders who contribute to the
innovation process and emphasizes the dynamic interac-
tion and knowledge flow between them [13]. To date
there has been little research on science-based health
product innovation in Rwanda. As far as the authors are
aware, this is the first study to explicitly look at this
topic in Rwanda.
The study was undertaken at the invitation of the for-
mer Minister in the Office of the President in charge of
Science and Technology. The 1994 genocide marked a
watershed moment for the country in general and the
national innovation system in particular. Most of the
already modest research base and private sector was
destroyed. Our evaluation of the innovation system has
this background context in looking at developments in
the post-genocide period of the last 15 years.
Methods
A case study research methodology was used in this
study [14]. Data were collected through reviews of aca-
demic literature and policy documents and through
open-ended, face-to-face interviews in Rwanda. Intervie-
wees were identified through purposive and snowball
sampling; we interviewed 38 people from across the
science-based health innovation system, including gov-
ernment officials (n=8), researchers in research institutes
and educational institutions (n=11), entrepreneurs (n=6),
international donors (n=2), and non-governmental orga-
nization representatives (n=5), over two visits to Rwanda
between November – December 2007 and in May 2008.
Given the important role of the members of the diaspora,
we also interviewed 6 members from them. Following the
interviews, a workshop was held in Kigali on May 23
rd
and May 24
th 2009 involving the interviewees and other
stakeholders to validate the findings. A business plan was
then developed to operationalize the findings. We report
the findings of our case study analysis below.
A l lq u o t e sa r ef r o mt h ei n t e r v i e w su n l e s sn o t e d ,a n d
with permission. This study was approved by the Office
of Research Ethics of the University of Toronto.
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In the following sections, we describe and discuss Rwan-
da’s science-based health innovation system.
Government
The integration of science and technology into the
country’s economic development has been given promi-
nence in Rwanda since 1994. President Kagame has
emphasized “the imperative of focusing and utilizing
science and technology,” to effect the country’sa n d
Africa’s socioeconomic transformation. In a speech to
the 8
th summit of the heads of state of the African
Union, President Kagame reiterated the importance of
innovation, saying “It is about applying science and tech-
nology holistically - in all levels of education and train-
ing, in ‘commercializing ideas’, developing business and
quickening the pace of wealth-creation and employment-
generation, in enabling government to provide better ser-
vices, and indeed in providing basic tools to society at
large for self- and collective betterment.”[15].
The guiding document for recent growth in science
and technology in Rwanda is the 2006 National Science,
Technology, Scientific Research and Innovation policy
[16]. Included in the policy are plans “to apply science
to Rwanda’s problems in health, agriculture and the
environment” by increasing crop yields and improving
animal husbandry through the use of biotechnology. In
addition, the policy paper envisions setting up district-
level ‘innovation centers’ and national technology parks
to encourage research and development, particularly by
small businesses.
Science and technology activities in Rwanda were
transferred to the Ministry of Education in 2009. Prior
to that, the Ministry in the Office of the President in
charge of Science and Technology was the central
agency in Rwanda’s science and technology model, and
directed both funding and research orientation. How-
ever, it was understaffed, with only four staff who had
to achieve the wide goals of the ministry as well as coor-
dinate all science and technology research and all
aspects of information communications technology in
Rwanda.
The Ministry’s 2009/2010 budget shows enhanced
commitment to innovation, with line items included for
establishing linkages between academia and industry
and for strengthening intellectual property.
Though the country lacks a biotechnology policy, this
remains one of the priority areas as alluded to by the
then Minister of Science and Technology Prof. Romain
Murenzi who when interviewed said, “I was thinking of
the need to establish a biotechnology authority that will
integrate biotechnology in health and agriculture”.H o w -
ever, a national bio-safety framework [17] was drafted in
2005, mainly to protect human health and the environ-
ment due to applications of biotechnology.
Rwanda’s public health goals are spelled out in the
“Health Sector Policy-Government of Rwanda” docu-
ment published in 2005 [18] among which is the
improvement of the availability of quality drugs, vac-
cines, and consumables and a goal to strengthen
national referral hospitals and research and treatment
institutions through collaboration with other ministries
and agencies. Within this document most of the
research focus is limited to clinical aspects of health as
opposed to health innovation.
As a “Least Developed Country”,R w a n d ai n2 0 0 8
became the first country to take advantage of the World
Trade Organization (WTO) amendment to the TRIPS
(Trade Related aspects of Intellectual Property) Agree-
ment [19], when it awarded a tender to the Canadian
generic manufacturer Apotex to manufacture the triple
combination AIDS drug “Apo Triavir” on its behalf. The
first shipment of 6.8 million pills arrived in Rwanda in
September 2008. The objective is to increase accessibil-
ity to cheap anti-retroviral (ARV) drugs to people with
AIDS in Rwanda, many of whom are poor. Government
officials stated that they hope by 2016, when the TRIPS
agreements take effect, Rwanda will have developed
capacity to manufacture its own pharmaceuticals.
An effective intellectual property regime is needed to
support innovation in Rwanda. Despite an intellectual
property law being passed by parliament in 2008, infor-
mation has yet to reach scientists, and this law has yet
to fully take effect. As put by Mark Bagabe, former
Director-General of the National Agricultural Research
Institute (ISAR), “We really have not internalized the
need to patent our research. We are still rebuilding and
focused on basic research and publication. In fact, as an
institute, we have lost so much patentable information
because of this”. There have been several missed oppor-
tunities where Rwanda could have benefited, but
because there are no proper policies on innovation man-
agement, the country has not benefited. For example, a
fertilizer was formulated at the Institut de Recherche
Scientifique et Technologique (IRST) by a scientist who
refused to disclose his formula; when he moved from
the institution, he went away with the knowledge. Bean
seed varieties developed at ISAR have also been found
being marketed in countries such as Malawi, yet the
Institute does not receive any royalties. And sericulture
lines developed by ISAR are not shared with the textile
industry in Rwanda.
Rwanda is a member of the WIPO convention, the
constituent instrument of the World Intellectual Prop-
erty organization. However, there are no IP attorneys in
Rwanda and respondents in this study doubted whether
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dle IP disputes. Another stated limitation which is com-
mon to many African countries was the high cost to
file, maintain, and enforce patents, all which are the
responsibility of the inventor; hence if the invention has
no immediate financial returns, there is reduced willing-
ness to attempt to patent.
Rwanda’s drug and medical product regulatory capa-
city is also very limited. The Food and Drug authority
has just been established but has yet to become fully
operational. Limited staffing and infrastructure issues, as
well as the porous nature of Rwanda’s borders, mean
that it is difficult to enforce drug quality and drug regis-
tration. Counterfeit products have been found in phar-
macies in Rwanda [20] and this is not only a drain on
the economy, because patients are wasting money, but
also a significant health risk.
Research institutes and universities
Like many African countries, the largest and most active
R & D institutions in Rwanda are public sector ones
involved in agricultural research. This is not surprising,
as the economy is heavily agrarian. The main focus has
been rural development and poverty alleviation, with lit-
tle emphasis on basic and applied R & D. Up until 1994,
political upheavals, changing budget priorities, staff
purges due to ethnic wrangles, and generally poor mor-
ale left institutions incapable of carrying out their core
mandates. Since then, investments in science and tech-
nology by the government and donors have improved
the situation.
At the base of the educational system, 96% of pri-
mary-school age children now receive free education
[10]. The percentage of students progressing from pri-
mary school to secondary school is still low, perhaps
due to absence of universal secondary school education.
But overall, there has been a very significant increase in
the number of students graduating from institutions of
higher learning in Rwanda over the last 15 years.
The number of students in higher learning institutions
increased from 10,000 in 2002 to 27,787 in 2005 [21].
Rwanda has six public and several private higher educa-
tion institutions [22]. Data from the 2003 census
showed that there were then 0.5% of university gradu-
ates in the population, compared to the African average
of 4%. However, the gross enrolment rate at tertiary
level was 3.2%, which is regionally comparable. Until
recently there was no graduate training at the National
University of Rwanda, forcing many students to be sent
abroad for training.
Institute of Scientific and Technological Research
The Institute of Scientific and Technological Research,
also known as the Institut de Recherche Scientifique et
Technologique (IRST), was established in 1989. It is the
country’s premier medical research institute, including
research in phyto-medicine, biodiversity, alternative
energy sources, environmental studies, and other fields
related to medicine. Its website indicates that there is a
department of biotechnology, but a visit to the institu-
tion revealed that this has not yet been established. The
Institute has acknowledged the importance of domestic
innovation and has established an innovation and tech-
nology transfer unit, as well as organized seminars to
sensitize its scientific staff on intellectual property man-
agement since 2005. According to the Institute’s Direc-
tor General Dr. Jean Nduwayezu, in 2007 the institute
had a total of 96 staff (88 involved in research) but only
6 PhDs (2 Rwandese nationals and 4 foreigners). He
also stated that the optimal number of staff required is
121, hence there is a shortfall of manpower.
The Centre for Research in Phyto-medicines and Life
Sciences at IRST carries out research in traditional
medicines, by liaising with traditional healers and carry-
ing out safety and anti-microbial efficacy tests. Material
is sent to international laboratories, mainly in Europe,
to carry out further investigation on plants that look
promising. This has proved difficult as they first have to
identify effective partners abroad. In some cases, results
of material sent abroad are never communicated back
to the scientists. Scientists expressed fear that they
could be losing intellectual property this way. As one
scientist remarked, “Sometimes all it needs is for an
experienced scientist with the necessary equipment to
establish anti-microbial properties of a plant. They then
go ahead and make derivatives from it that are active
against different pathogens and patent it claiming it to
be theirs”.
Currently the main focus is testing for toxicity using
mice on traditional plants submitted by the traditional
healers. After ascertaining safety, the institute’sl o g oi s
usually affixed on the product which allows the tradi-
tional practitioner to market the product. Examples of
traditional medicine extracts now being marketed
include products for such mild common ailments as
diarrhoea and common colds as well as ointments to
relieve pain. An earlier survey of traditional medicinal
products [23] showed examples of such medicines to
include an anti-spasmodic syrup from Datura stramo-
nium (Gifurina), anti-cough syrup from Plantago lanceo-
lata (Bentakor), cough syrups from the mixture of
Eucalyptus globulus and Datura stramonium (Tusinkor),
and from Eucalyptus globulus, Datura stramonium and
Thymus vulgaris (Tumitusilinga), a mouth disinfectant
solution from Eucalyptus globulus and Mentha sacchali-
nensis (Kanwalina), an anti-arthritic formulation from
Capsicum frutescens, an anti-inflammatory ointment
from Calendula officinalis (Calendula) and an antisca-
bies ointment ‘Tembatembe A’ containing a rotenone
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successfully on prisoners.
National Agricultural Research Institute
The National Agricultural Research Institute, also
k n o w na st h eI n s t i t u td e sS c i e n c e sA g r o n o m i q u e sd u
Rwanda (ISAR), is Rwanda’s major agricultural R&D
agency. ISAR, the oldest scientific research institution in
Rwanda, was rebuilt after the 1994 war; this included
the construction of new laboratories and installation of
modern scientific equipment. Many staff members have
received international training (Masters and PhD) and
today the institute can be described as the institution
that has the best capabilities within Rwanda to carry out
basic biotechnology research. The institute has the capa-
city to carry out limited molecular biology techniques,
tissue culture, and food fortification. However, at the
time of the study it had no clear IP policy and very little
focus on innovation. Like most other research institutes
in Rwanda, there had been very little linkages with the
private sector.
In addition to the above two research institutes, higher
education institutions in Rwanda are participating in
research.
National University of Rwanda
The National University of Rwanda is the country’sb i g -
gest university and was established in 1963. Located at
Butare, it offers a wide range of degree programs. It has
also developed a new strategic plan in which great
emphasis has been placed on scientific innovation. The
Faculty of Agriculture and the School of Medicine are
the departments that are actively involved in health
related research. However, because of the high student
to staff ratios at the university, resources are heavily
skewed towards teaching at the expense of research. As
one professor remarked, “Our focus at the moment is to
teach. Because we have very many students compared to
the number of staff, we cannot conduct any research.”
Other limitations include lack of scientific infrastructure
as well as general funding. Currently, most health
research is limited to epidemiological studies and clini-
cal research on behalf of international organizations and
foreign university researchers.
Kigali Institute of Science and Technology
Kigali Institute of Science and Technology (KIST) was
the first public technological institute of higher learning
in Rwanda. Though originally established as a technol-
ogy and engineering institution in 1997, it has expanded
its curriculum to many other areas including health
sciences and now offer degrees in various subject areas.
In 2009, it established a faculty of medical biotechnol-
ogy, to train both undergraduate and graduate students.
As the Rector, Prof. Abraham Atta Ogwu said, “We rea-
lized the future importance that medical biotechnology
will play in trying to address Rwanda’sh e a l t hn e e d s ,
and that is why we decided to be the first institution in
Rwanda to offer training specifically geared towards
medical biotechnology”. KIST has also established the
Centre for Innovation and Technology Transfer to
develop appropriate technology solutions for rural areas
and has an incubation facility that nurtures young entre-
preneurs, providing basic facilities and business manage-
ment training services to them.
According to Ministry of science officials, KIST is
more adaptable to the country’s needs because it does
not have historical bureaucracy that other institutions
that have been there for a long time face. In addition
there are many international visiting scholars at the
institution as well as international collaborative agree-
ments with other institutions enabling knowledge
exchange that is critical for developing skills in
innovation.
Though it was difficult to obtain, for any of the coun-
try’s institutions, the allocation of research budgets
across salaries and capital costs, there was clear evidence
that the bulk of resources are currently allocated
towards operating costs, thereby affecting the efficiency
of R & D.
Private sector
Rwanda’s private sector is nascent, with most businesses
being small scale and with low technology enterprises.
From the interviews many entrepreneurs were young
and were western educated mainly in the United States
and Britain and had only returned to the country in the
late 1990s or early 2000`s.
Private sector investors have not generally been
involved in exploiting any potential opportunities from
research, let alone from research in health or
biotechnology.
One firm that has tried to produce local health pro-
ducts is Ikirezi Natural Products, a firm that has been
involved in extraction and export of geranium oil, which
is used as an essential oil in remedies for dermatological
conditions. According to the founder, this has generated
significant economic benefits to farmers, as the value
from the same acreage of land for geranium is much
higher than for coffee and tea – demonstrating the
potential of alternative crops.
Also interested in health technology is Rwanda’sl a r -
gest industrial manufacturer, Utexrwa, which specializes
in textile manufacture. The company CEO has
expressed interest in manufacture of pyrethrum impreg-
nated mosquito nets which would serve two purposes:
provide a market for pyrethrum that is currently being
exported unprocessed outside the country, and save the
importation of long lasting mosquito nets. There are
talks between the firm and universities in Canada about
developing technology that could use pyrethrum to
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cide-treated Mosquito nets.
One other area examined in this study was access to
risk capital and credit. We identified at least four ven-
ture capital firms in the city of Kigali, plus several bank-
ing and micro-finance institutions. The Rwandan
Enterprise Investment Company (REIC) is the largest
such provider of risk capital. The company’s legal foun-
dation, established by an act of Parliament, is viewed as
a source of strength as it is a public institution with pri-
vate sector goals. Its primary responsibility is to govern-
ment, but it has autonomy in its investment decision
making. The organization has the mandate of financing
projects which have both commercial and social bene-
fits. According to the CEO of REIC, the major limitation
to investment in health R & D has been the inability for
them to determine the commercial viability of health
research in Rwanda. “We have this mandate towards
looking at key core areas that need financing because
nobody else is willing to finance them” says Mike Kagwa,
its CEO. “If health is an asset that can be structured, we
will be in it. Not many people know how to structure
health research as a viable asset and we don’tk n o w
where the commercial gain is, except social benefits”.
Foreign venture investors, especially American firms,
can also be found in Rwanda. While many are driven by
their conscience to help rebuild the country, a number
of them are simply looking for potential profits that can
be reaped from a country that is starting from scratch,
as there is very little domestic competition. “My inves-
tors are hard-nosed capitalists”, says American trained
Antoine Bigirimana, CEO of Kigali based Thousand
Hills Venture Capital. “They are simply looking for ideas
that are easy winners”.
However, there is a lack of connection between capital
providers and researchers in the university and research
institutes. This is due to the absence of knowledge flow
and of venues in which they can meet and exchange
ideas. When asked, most researchers in Rwanda were
unaware of the existence of local venture capitalists,
while the venture capitalists were also unaware of the
fact that there might be technologies stagnating on
shelves in local institutions.
Private sector entrepreneurs in Rwanda are organized
under the Rwandan Private Sector Foundation. We were
informed by one of the interviewees that this umbrella
organization of businesses in Rwanda has eight regional
centres where it trains small business management
skills. There are also a number of micro-finance institu-
tions that mainly support small businesses by providing
them with loans and business training.
The only pharmaceutical manufacturer in Rwanda is
the government owned Pharmaceutical Laboratory of
Rwanda (LABOPHAR). After years of loss making it was
recommended for privatization. The company was initi-
ally set up to manufacture quinine and a variety of gen-
eric products, but has been limited to manufacturing
intravenous fluids and water for injection, i.e. bulk pro-
ducts that cannot be imported and yet are necessary for
the country’s hospitals. According to some interviewees,
the poor performance of the company is mainly attribu-
ted to lack of technical know-how, lack of infrastructure,
poor management, and the fact that it was a govern-
ment-run institution without the drive of private entre-
preneurship. It thus became a burden to the Rwandan
tax payer, hence its privatization.
Drug distribution in Rwanda also appears ad-hoc,
mainly because the drug regulatory agency has not been
fully staffed. Individuals can import any products with-
out any restrictions or assessment on their quality. As
such, many pharmacies in Rwanda import directly,
mainly from India and Kenya. CAMERWA is the gov-
ernment agency charged with drug procurement and
distribution and mainly supplies government-run hospi-
tals with drugs, all of which are funded by donor agen-
cies. The agency is reasonably well staffed at the
national office, but lacks the infrastructure needed to
ensure successful national distribution.
Innovation is also affected by market factors. The
domestic market in Rwanda is small, both in size and
purchasing power, hence demand for products is lim-
ited. This tends to affect the quantity and type of pro-
ducts that are developed for the Rwandan market by
domestic and international enterprises.
Overall, Rwanda’s general business climate is well-
regarded in comparison to its neighbouring countries in
the East African Community and in Africa in general.
For example, Rwanda has less corruption and bureau-
cracy than the regional standards, and the time taken to
start a business is shorter than the average for sub-
Saharan Africa – all factors which make local science-
based health innovation easier. Some business issues
that Rwanda is currently addressing include legal and
regulatory constraints as well as improvements to enfor-
cement and employment practices.
NGOs and donors
Non-governmental organizations and donors also influ-
ence Rwanda’s science-based health innovation. The
Rwandan government receives more foreign aid per
capita than most countries in Sub-Saharan Africa [24].
This aid is delivered through a mix of budget support
and project financing. At its peak in 2005, 60% of the
national budget was directly funded by donors. Many
interviewees said that because scientific research in
Rwanda is largely financed by donors and multilateral
development banks, channelled through both the
national government and project support directly to
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various lines of research reflects donor influence. Most
donors fund specific programs within their traditional
areas of interest. Thus the European Union funded con-
struction and equipment of a coffee research laboratory
at ISAR to stimulate coffee research, reflecting their
priority of agriculture.
The government has made efforts to gradually reduce
this to just over 40 % in 2009. According to officials in
the Ministry in charge of science, the main donors in
science and technology are the World Bank, the African
Development Bank, and the British international devel-
opment agency, DFID. DFID is currently assisting in the
development of an institutional framework within the
Ministry of Science and Technology that will, among
other things, support innovation platforms. The World
Bank is working on programs that enhance scientific
capacity, focusing on value addition of agricultural pro-
ducts. The aim of this World Bank project is to foster
economic growth by creating jobs and wealth through
building an economy that is driven by innovation and
higher-value production systems.
In 2006/7, the African Development Bank, through the
science and technology sector budget support, assisted
in drafting the Science and Technology in Education
work plan. This plan, which has been put in place, aims
to foster the teaching of science and technology from
the primary school level with the provision of science
corners in all schools. At the secondary school level,
plans include the building of science labs. Vocational
and technical schools in Rwanda are also to be reno-
vated and equipped to provide effective education
geared to the labor market.
Ministry of Science officials also told us that colla-
borative programs with institutions in the US and other
developed countries have also been established with the
main purpose of providing training to Rwandese scien-
tists. These include Carnegie Mellon and Massachusetts
Institute of Technology (MIT) whereby students from
Rwanda are given scholarships to train at these institu-
tions in the fields of computer science and engineering.
The Government of Rwanda has also established a Pre-
sidential Scholars program in collaboration with univer-
sities in the US that enables Rwanda’s best math and
science students to receive four-year scholarships to do
their undergraduate studies at US colleges and universi-
ties. The major institution supporting the Presidential
Scholars program is Oklahoma Christian University.
The focus of the studies are civil and electrical engineer-
ing, computer science, chemistry, and architecture, and
biotechnology, areas of study deemed critical to Rwan-
da’s long-term, economic development plans.
The National Treatment and Research AIDS Center
(TRAC) is a non-governmental organization that tries to
shape health policy in Rwanda using treatment out-
comes. TRAC partnered with the software company
Voxiva to develop an integrated software system for
monitoring diseases in Rwanda. Using both web-based
software and mobile phones, TRACNET collects, stores,
retrieves, displays and disseminates critical program
information, as well as managing drug distribution and
patient information related to the care and treatment of
HIV/AIDS.
Diaspora
The displacement of many of Rwanda’s citizens because
of historical strife resulted in a large Rwandan diaspora.
According to the Ministry of Foreign Affairs, an esti-
mated 6 million people of Rwandese descent live abroad,
mainly in Europe and North America; this number is
over half the entire population of people living in
Rwanda. This significant resource can act as a source of
revenue through remittances and direct investments, as
well as a pool from which to draw ideas, skills, attitudes
and technologies. Discussions with Jean Kimanzi, Presi-
dent of Rwandan Diaspora, revealed that there are
already two programs – Transfer of Knowledge Through
Expatriate Nationals (TOKTEN) and MIDAS – that
enable qualified Rwandese in the diaspora to travel back
to Rwanda periodically to assist in transfer of knowl-
edge. These programs aim to supply Rwanda with short-
term expertise not readily and immediately available
locally. “The environment is right. There is political will
and Rwandese should take advantage of this to give
something back to their country” remarks Dr. Kimanzi.
Conclusions
Strengths and good practices
Rwanda’s science-based health innovation system
including biotechnology has several strengths, which
include liberal policies on employment of expatriates,
the clustering of its academic and research institutes in
one main geographical area, and the multi-lingual nat-
ure of the population, which means that it is easier for
Rwanda to trade with many countries.
Perhaps the greatest strength of Rwanda’s science and
technology system is the political support and dynamic
leadership that the country is currently experiencing,
especially from the country’s President, Paul Kagame.
This was cited by many respondents who also men-
tioned the fact that the country has made dramatic
investments in science and technology. According to the
President, Rwanda currently invests 1.6% of its GDP on
Science and Technology [25]. The country has also
developed a strong science, technology and innovation
policy, meaning that Rwanda has realized the need to
incorporate STI in its economic development agenda.
Activities to implement the policy have already started
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based on the STI policy and recommended practical
solutions to some of Rwanda’s problems [26]. The main
area of focus was value addition to agricultural products.
The 2009 government budget provided funds (approxi-
mately 100, 000 dollars) to support innovation activities.
These funds can be accessed by any scientist or entre-
preneur. An initial disbursement of these funds was
made to support projects in KIST and ISAR; one on the
use of banana fibres in textiles and the other on sericul-
ture development in Rwanda. From interviews with gov-
ernment officials, it also appears that the government
readily welcomes donors and international institutions
that are willing to help it strengthen science activities in
Rwanda.
H o w e v e r ,w h i l eR w a n d ah a sag o o dS T Ip o l i c y ,S T I
activities in the country are mainly focused on the
development of information technology with little focus
on health and health biotechnology. The reasoning
behind this is that Rwanda aims to become the informa-
tion technology hub of Africa. Information technology
has become very useful in supporting health programs
in Rwanda, as evidenced from the TRACNET program.
However, interviewees mentioned that health innovation
is not sufficiently mentioned in the STI policy.
The main opportunities in science-based health inno-
vation and biotechnology for Rwanda are in traditional
plant technologies (see Table 1 for selected opportu-
nities). Interviewees repeatedly cited this as the area of
greatest potential. Reasons included the existence of
IRST (an institute that has some capacity to carry out
research in traditional medicines), the ready availability
of a variety of traditional plants, and the experience of
traditional plant healers. Health-related information
technology was also identified as an area with great
potential. Many interviewees gave the reason for this to
be the well developed information infrastructure in the
country, as well as the government’s inclination to sup-
port information technology policies.
Recommendations
From the interviews, we can conclude that there are
specific challenges that need to be overcome for Rwanda
to successfully exploit its science-based health innova-
tion and biotechnology. When we interviewed the man-
agement of the various research institutions, they cited
deficiency in scientific infrastructure and a shortfall in
the number of trained scientists who are capable of car-
rying out advanced health biotechnology research as one
of the major challenges. Specifically, many interviewees
cited the low number of people trained in molecular
biology techniques as a hindrance to development of the
sector. Post-graduate opportunities within Rwanda are
limited, particularly within health biotechnology.
In addition, there is a skewed distribution of health
researchers in favour of teaching at academic institu-
tions. This has contributed to the dismally low number
of research publications by local Rwandan scientists,
which total only 30 research articles published between
2002 and 2004. From the interviews, many of the scien-
tists did not appear able or sufficiently motivated to
pursue entrepreneurial activities as most do not consider
research to be rewarding.
The brain drain that occurred during earlier years in
the country’s history continues to plague science and
technology. This was made worse by the genocide, dur-
ing which scientists were among those who were killed
or fled to other countries in the region and abroad.
While a few have returned and formed part of the inter-
view pool, many are still abroad. However, this may also
Table 1 Various products and processes being developed in Rwandan institutions
Product General Area Organization Description
Traditional herbal medicines
-Gifurina-Datura stramonium
-Bentakor-P. Lanceolata
-Tusinkor-E.globulus
-Tumitusilinga-T.Vulgaris
-Kanwalina-M.Sacchalinensis
-Calendula-C.officinalis
-Tembatembe A-N.Mitis.
Anti-spasmodic
Anti-cough
Anti-cough
Oral disinfectant
Anti-arthritic
Anti-
inflammatory
Scabies
IRST Whole plant extracts. Adoption of existing practices by traditional healers and
carry out safety and efficacy tests
Essential oils-Geranium Cosmetics /
Dermatology
IKIREZI Natural
products
Extraction of essential oils from geranium plant
Intravenous fluids and water for
injection
Laborphor For use in hospitals, since transport costs for this bulky product are high
Pyrethrum treated long lasting
mosquito nets
Malaria Utexrwa Concept under development with researchers from Canada
Health information technology
software
Health IT TRAC Developing software for integrating health information, in partnership with
Voxiva.
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of highly qualified individuals who left the country
either as refugees or to pursue higher education in the
West. When interviewed, many members of the dia-
spora said that since they are now occupying senior
positions in new countries, they are unwilling to return
to Rwanda, but they could lend their skills to support
development of health biotechnology if appropriate poli-
cies are put in place.
Another problem is brain drain within the country,
mainly as a result of a serious mismatch between cap-
abilities, opportunities and compensation of scientists
within Rwanda. Interviewees repeatedly cited the efflux
of researchers from university and research institutes
towards sectors that do not engage in research, such as
NGOs that offer attractive work environments and
higher salaries.
Discussions with scientists showed that a career in
politics has become a very attractive field for Rwandan
scientists. Indeed, a close examination of the Rwandan
Cabinet and Parliament reveals a contingent of very
highly trained professionals, many of whom possess
advanced degrees in biotechnology, engineering, or
health and significant research experience. This illus-
trates the internal brain drain phenomenon, although it
may be argued that having a scientifically literate politi-
cal establishment has contributed to increased support
for science and technology.
We can deduce from the study that science-based
health innovation and biotechnology in Rwanda is cur-
rently fragmented, with training and scientific research
falling under many different agencies. For example, uni-
versities fall under the Ministry of Education, while
research institutes fall under different ministries includ-
ing the Ministry of Agriculture (e.g ISAR, ISAE) and the
Minister in President’s Office in Charge of Science,
Technology, Scientific Research, and Information Com-
munication Technologies (e.g ISTR). From the inter-
views it was apparent that the government has
continued to fund R&D institutes and universities with-
out paying much attention to the quality of research
being conducted, the use of research outputs, or the
relationship of research to the country’s economic,
scientific, or market priorities. Neither does it appear
that efforts have been made to stimulate linkages
between the private sector and the universities and
research institutes in Rwanda. Most scientists inter-
viewed did not seem to know what other research insti-
tutes were doing, nor were there institutional
mechanisms to outsource their knowledge to the private
sector players like venture capitalists.
In order to successfully exploit the potential of
science-based health innovation and biotechnology in
Rwanda, several recommendations can be made.
Recommendation 1: Strengthen the skills base: For a
country with limited resources like Rwanda, investment
in knowledge arguably is critical to development.
Rwanda should promote the training of its scientists in
order to develop a scientific pool that can spur health
innovation. This can be done through domestic, regio-
nal, and overseas institutions. We realize that this will
require considerable resource s ,b u to n es o u r c eo fs k i l l s
and training staff is the Rwandan diaspora who can be
encouraged through incentives to provide short-term
training to scientists in Rwanda. Attaching skilled mem-
b e r so ft h ed i a s p o r at ou n i v e r s i t i e si nR w a n d aw i l l
reduce costs of sending students abroad. Because of its
strong links with international institutions, online
courses could also be used whereby staff from western
universities give lectures on scientific areas as well as on
entrepreneurship.
Carrying out an audit of the personnel and scientific
infrastructure available in Rwanda will help identify
areas that need strengthening. To reduce brain drain, it
is important that the government provides incentives
through reasonable wages for scientists and clear pro-
motion paths as well as facilities for scientists to be able
to carry out their work. Institutions should develop IP
policies that reward individuals who are innovative.
Recommendation 2: Encourage the establishment of R
& D within private sector firms: The government can do
this by creating a favourable business environment for
firms that want to engage in R & D. Firms like Utexrwa
which have already indicated willingness to engage in
health innovation might be incentivized. This could be
through tax incentives on research equipment and raw
materials, as well as local “advance market commit-
ments”, whereby the Ministry of Health guarantees pur-
chase of products developed locally as long as they meet
internationally accepted standards. Strengthening of
intellectual property regimes and increasing awareness
of IP by scientists will be helpful. There is also need to
support innovative activities by providing funds that
scientists and entrepreneurs can access, such as proto-
type or product development funds in the form of
grants or loans.
Recommendation 3: Establish a focal point for science-
based health and biotechnology development: There is
need to coordinate R & D and innovation at the
national level. Currently, there is no National Science
Council or Commission which could be the body
charged with coordinating research in Rwanda. While
the government has established the Rwanda Biomedical
Centre (RBC) which merges 15 medical institutions in
the country, the focus is limited to clinical research. A
council would be charged with capturing the innovative
components of biotechnology research. This body would
direct sectoral policies – e.g developing a national
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rities of the government in terms of health innovation
development, as well as concrete actionable steps to rea-
lize these goals. It could also identify an institution that
will be a centre of excellence for biotechnology. This
centre could be equipped with individuals possessing
the necessary skills to excel in biotechnology research,
as well as the necessary scientific infrastructure, and a
mandate to establish relationships between firms and
research institutions.
Recommendation 4: Establish R & D infrastructure
and platforms through which knowledge flows from the
country’s research institutions will flow to firms in the
private sector and vice versa: These could be in the
form of physical platforms or virtual networks [27]. The
centres will be equipped with state of the art specialized
equipment. From the interviews, scientists cited the lack
of advanced equipment as a hindrance to R & D and
gave examples of equipment like nuclear magnetic reso-
nance (NMR) machines and high-performance liquid
chromatography machines (HPLCs) that do not cur-
rently exist in Rwanda. Many types of research instru-
ments are very expensive for individual institutes to buy
and maintain. Such a centre can be centrally located,
and its facilities accessed by scientists from various insti-
tutions as required.
The aim of this study was to describe and analyze
Rwanda’s science-based health innovation and biotech-
nology sector. In doing so we also involved the stake-
holders who constitute this sector in developing options
to harness Rwanda’s assets and begin to overcome
barriers.
Since the completion of our study, we have continued
to work with the Ministry of Science and Technology
and subsequently the Ministry of Education, to address
some of the key challenges we identified in our case
study. We jointly hosted a national life sciences work-
shop held in May 2008 in Kigali where we presented
our case study results and recommendations, which
were discussed with local stakeholders including govern-
ment officials, the private sector and the research com-
munity. Stakeholders agreed unanimously with the
results and recommendations, especially the need to
increase knowledge flow. They supported the idea of
developing a life sciences innovation center [28]. Since
the meeting, an initial disbursement of funds to two
projects has been done, and discussions are underway
on where the initial start-up activities are to be physi-
cally located.
From the study, the main conclusion that can be
drawn is that Rwanda is a late bloomer in science-based
health innovation and biotechnology, mainly because of
events preceding and during the 1994 genocide. There
is very little innovative activity occurring in the
institutions or in the private sector. The number of
scientists is still very low, and even those who are pre-
sent are not generally motivated to carry out innovation.
However, because Rwanda is still at an early stage in
developing its institutions, it is well positioned to shape
its institutions in line with current challenges in
science-based health innovation and biotechnology; its
institutions are not bogged down by the bureaucracy
and rigidity that characteri z em a n ym o r e - e s t a b l i s h e d
institutions in Africa [29]. Many of the staff in its insti-
tutions are young and amenable to change, and could
easily embrace innovation if properly motivated. In addi-
tion the country enjoys enormous goodwill among the
donor community to implement many initiatives that
the government proposes. It also has a large pool of
skilled people in the diaspora who are willing to contri-
bute towards developing their homeland. Building on
these assets and strong political commitment, Rwanda
has the potential to make effective use of science-based
health innovation.
Acknowledgements
Helpful comments and suggestions were received from Jocalyn Clark, Sara
Al-Bader, Halla Thorsteinsdóttir, Wesley Ronoh, Hassan Masum, Padmashree
Sampath and Oyebanji Oyeyinka. We are also grateful to the Hon. Minister
Murenzi, former Minister of Science and Technology ( Rwanda) and his team
for the initial invitation to undertake this study and the support they
provided. This study was funded by the Canadian Institutes of Health
Research through a Michael Smith award to Dr. Singer. The McLaughlin-
Rotman Centre for Global Health, Program on Ethics and Commercialization
is also supported by the Bill & Melinda Gates Foundation and other partners
listed at http://www.mrcglobal.org.
This article has been published as part of BMC International Health and
Human Rights Volume 10 Supplement 1, 2010: Health innovation in sub-
Saharan Africa. The full contents of the supplement are available online at
http://www.biomedcentral.com/1472-698X/10?issue=S1.
Author details
1McLaughlin-Rotman Centre for Global Health, at the University Health
Network and University of Toronto, MaRS Centre, South Tower, Suite 406,
101 College Street, Toronto, Ontario, M5G 1L7, Canada.
2Ministry of
Education, Rwanda.
Authors’ contributions
KS, PAS, ASD contributed to the concept and design of this study and
participated in site visits, analyzed the findings, and participated in
manuscript development. MH participated in site visits, and participated in
manuscript development.
Competing interests
None declared.
Published: 13 December 2010
References
1. World Economic Forum: Rwanda. Investment climate profile. 2009,
Geneva.
2. WorldBank. 2009 data from Development Economics LDB database.
[http://data.worldbank.org/country/rwanda].
3. WorldBank. 2009 data from Development Economics LDB database.
[http://data.worldbank.org/country/rwanda].
4. WorldBank. 2009 data from Development Economics LDB database.
[http://data.worldbank.org/country/rwanda].
Simiyu et al. BMC International Health and Human Rights 2010, 10(Suppl 1):S3
http://www.biomedcentral.com/1472-698X/10/S1/S3
Page 10 of 115. WorldBank. 2009 data from Development Economics LDB database.
[http://data.worldbank.org/country/rwanda].
6. World Health Organization: Rwanda Health System Fact Sheet. 2009,
Geneva.
7. Knowledge Economy Index 2009. [http://info.worldbank.org/etools/kam2/
kam_page5.asp].
8. Mouton J, Waast R: Mapping Research Systems in Developing Countries:
Synthesis Report. Paris, France: UNESCO; 2008.
9. Pouris A, Pouris A: The State of Science and Technology in Africa (2000-
2004): A Scientometric Assessment. Scientometrics 2009, 79(2):297-309.
10. Ministry of Education (Mineduc). [http://www.mineduc.gov.rw/spip.php?
article20], (Accessed 1 June 2010).
11. World Economic Forum: The Africa Competitiveness Report 2009. 2009,
Geneva.
12. van Beuzekom B, Arundel A: OECD Biotechnology Statistics 2009. Paris,
France: OECD; 2009.
13. National Systems of Innovation: Towards a Theory of Innovation and
Interactive Learning. London: Pinter Publishers;Lundvall BÅ 1992.
14. Yin R: Case Study Research. Design and Methods. California: Sage
Publications;, Third 2002.
15. President of the Republic of Rwanda. Address to the 8th African Union
Summit on “Science, Technology and Research for Africa’s
Development”. Addis Ababa, Ethiopia. 29 January 2007.
[http://www.africa-union.org/root/AU/Conferences/Past/2007/January/
summit/speeches.htm].
16. National Science, Technology, Scientific Research And Innovation Policy
2006. [http://www.primature.gov.rw/index2.php?
option=com_docman&task=doc_view&gid=868&Itemid=95].
17. The National Biosafety Framework for Rwanda. August 2005.
[http://www.unep.org/Biosafety/files/RWNBFrep.pdf].
18. Government of Rwanda: Health Sector Policy. 2005.
19. WTO | intellectual property (TRIPS) - Amendment of the TRIPS
Agreement. [http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm].
20. Kayumba PC, Risha PG, Shewiyo D, Msami A, Masuki G, Ameye D,
Vergote G, Ntawukuliryayo JD, Remon JP, Vervaet C: The quality of
essential antimicrobial and antimalarial drugs marketed in Rwanda and
Tanzania: influence of tropical storage conditions on in vitro dissolution.
Journal of Clinical Pharmacy and Therapeutics 2004, 29(4):331-338.
21. Ministry of Education (Mineduc). [http://www.mineduc.gov.rw/], (Accessed
1 June 2010).
22. World Bank: Education in Rwanda: Rebalancing Resources to Accelerate
Post-Conflict Development and Poverty Reduction. 2004, Washington D.C.
23. United Nations Development Programme (UNDP): Rwanda Annual Report.
2000, Kigali, Rwanda.
24. Rwanda – African Development Bank. [http://www.afdb.org/en/countries/
east-africa/rwanda/], (Accesed 1 June 2010).
25. The African Executive | Science, Technology and Innovation In Africa.
[http://www.africanexecutive.com/modules/magazine/article_print.php?
article=3061].
26. World Bank: Building Science, Technology, and Innovation Capacity in
Rwanda. Developing Practical Solutions to Practical Problems. 2008,
Washington, D.C.
27. Masum H, Daar AS, Al-Bader S, Shah R, Singer PA: Accelerating Health
Product Innovation in sub-Saharan Africa. Innovations Journal 2007,
2:129-149.
28. Kamunyori S, Al-Bader S, Shah R, Simiyu K, Singer PA, Daar AS: Accelerating
African Health Innovation. The Africa Journal. 2008, 20-21.
29. Ayittey GBN: Africa Unchained: The Blueprint for Africa’s Future.
Basingstoke, England: Palgrave Macmillan; 2004.
doi:10.1186/1472-698X-10-S1-S3
Cite this article as: Simiyu et al.: Science-based health innovation in
Rwanda: unlocking the potential of a late bloomer. BMC International
Health and Human Rights 2010 10(Suppl 1):S3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Simiyu et al. BMC International Health and Human Rights 2010, 10(Suppl 1):S3
http://www.biomedcentral.com/1472-698X/10/S1/S3
Page 11 of 11